Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00171535
- Lead Sponsor
- Novartis
- Brief Summary
This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- Patients with severe hypertension
Exclusion Criteria
- History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- Liver, kidney, or pancreas disease
- Insulin dependent diabetes
- Allergy to certain medications used to treat high blood pressure
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Adverse events and serious adverse events at each study visit for 6 weeks
- Secondary Outcome Measures
Name Time Method Sitting and standing blood pressure measurements after 6 weeks Laboratory test data after 6 weeks Vital signs at each study visit for 6 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States